BioStem Technologies CEO sells 14,300 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BioStem Technologies, Inc. Chief Executive Officer, director and 10% owner Jason Matuszewski sold 14,300 common shares at $1.00 per share on November 17, 2026, to cover tax obligations connected with exercising vested options. His direct common-share holdings after the sale were 1,539,251; no Rule 10b5-1 plan was reported for the sale. The report also lists direct options covering 2,000,000 common shares at $2.00, 198,807 and 40,427 shares at $10.05, and 440,529 shares at $5.50, with expirations from October 24, 2032, through February 11, 2036.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 14,300 | $1.00 | $14K |
| Holding | Series A-1 Convertible Preferred Shares F2, F3 | -- | -- | -- |
| Holding | Options (Right to Buy) F4 | -- | -- | -- |
| Holding | Options (Right to Buy) F5 | -- | -- | -- |
| Holding | Options (Right to Buy) F6 | -- | -- | -- |
| Holding | Options (Right to Buy) F7 | -- | -- | -- |
| Holding | Restricted Stock Units F8, F9 | -- | -- | -- |
| Holding | Restricted Stock Units F8, F10 | -- | -- | -- |
| Holding | Restricted Stock Units F8, F11 | -- | -- | -- |
Footnotes (11)
- F1. Represents shares sold to cover the Reporting Person's tax obligation in connection with the exercise of vested options to purchase shares of the Issuer's Common Stock.
- F2. The Series A-1 Preferred Convertible Stock is convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Preferred Stock.
- F3. The Series A-1 Preferred Convertible Stock has no expiration date.
- F4. These options are fully vested and exercisable.
- F5. These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F6. These options vest according to the following schedule: 33% vested on October 13, 2026, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F7. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F8. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F9. These restricted stock units vest in equal quarterly installments over three year from the grant date (September 15, 2024).
- F10. These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
- F11. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Key Figures
Key Terms
vested options technical
Series A-1 Preferred Convertible Stock technical
one-to-one basis technical
restricted stock units financial
contingent right technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.